BioCryst 制药 BCRX
$7.69 +$0.06 (+0.79%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $7.71 +0.26%
开盘$7.81
昨收$7.63
当日区间$7.38 – $7.83
成交量5.21M
市值$1.98B
市盈率（TTM）–
股息率–
BCRX 相关新闻
匹配 BioCryst Pharmaceuticals 或代码 BCRX 的头条新闻，按最新排序。
- Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
- J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 正面
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11 负面
- H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
- RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 负面
- Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating 正面
- Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20 负面
- RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating 正面
- TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30
- RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14 正面
暂无评论——快来第一个聊聊 BCRX。